Navigation Links
Regular Acupressure May Reduce Agitated Behavior in Dementia

A study published in the February issue of the UK-based Journal of Clinical Nursing, shows that Acupressure can significantly reduce agitated behaviour in older patients// with dementia.

Researchers at the National Yang-Ming University in Taiwan found that providing 15-minute treatment sessions twice a day for five days a week yielded considerable benefits, including reductions in verbal and physical attacks and wandering.

But once the four-week treatment period ended, agitation levels started to rise again, suggesting that acupressure needs to be provided on an ongoing basis.

20 patients were studied over six weeks, including one week before the treatment started and one week after it finished. All lived in dementia special care units at a long-term care facility.

70 per cent of the patients suffered from severe behavioural disturbances, with a further five per cent suffering from extremely severe impairment. The remaining 25 per cent were classed as medium.

An average pre-treatment score of just over 79 was recorded on a specialist scale developed to measure agitation levels. After four weeks' treatment this had fallen to just under 60.

Pre-treatment agitation was highest in the 65-59 and 80 plus age groups (82 and 97 respectively) and in males (83).

"Agitated behaviour in people with dementia is a major concern for caregivers" says co-author Professor Li-Chan Lin from the Institute of Clinical Nursing at National Yang-Ming University, Taiwan. "It can endanger patients and others, make it necessary for them to be moved from familiar surroundings and demoralise and psychologically distress caregivers.

"People are living longer and, as a result, we face increased numbers of people with dementia. It is very important that we find interventions that enable us to provide more effective care for them, both in their own home and in long-term care facilities."


'"/>




Page: 1 2

Related medicine news :

1. Startling Expose – Physicians Often Have No Regular Source Of Health Car
2. Regular exercise prevents hip fractures
3. Regular exercise linked to extended menstrual cycles
4. Regular Use Of Cocaine Can Impair Brain Functions
5. Experts Insist That Neonatal Herpes Be Reported Regularly
6. Regular light exercise slows down aging of the brain
7. Wounds Heal 25% Faster In Older Adults Who Exercise Regularly
8. Children Need Regular Fluoride Varnishes
9. How Healthy Is A Regular Dose Of Cod Liver Oil?
10. Women Fail to Take Calcium Pills Regularly; High Risk of Bone Fractures
11. Regular Exercise Is Essential To Keep Arteries Healthy
Post Your Comments:
Other Medicine News:Health News:Express Scripts Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of WellPoint's NextRx Subsidiaries 2Health News:CVS/pharmacy Introduces New Coupon Center on CVS.com 2Health News:Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program 2Health News:Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program 3Health News:Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program 4Health News:Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program 5Health News:Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program 6Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 2Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 3Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 4Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 5Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 6Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 7Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 8Health News:iUniverse Hosts Canadian Storytellers, Cystic Fibrosis Awareness Advocate for BookExpo America 2009 Book Signings 2Health News:New Website, ElasticBandageStore.com, Offers Elastic Bandages at Wholesale Prices 2
Breaking Medicine Technology:RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 2RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 3AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Marc Russo Named Vice President of Senior Markets at Blue Shield of California 57132 1Marc Russo Named Vice President of Senior Markets at Blue Shield of California 57132 2MUSC Researchers Concerned About Online Drug Availability 57128 1MUSC Researchers Concerned About Online Drug Availability 57128 2HealthSouth Declares Dividend on 6 5 25 Series A Convertible Perpetual Preferred Stock 57123 1